Atlas Trials

A Study to Evaluate the Safety, Tolerance and Initial Efficacy of EGFRvIII CAR-T on Glioblastoma

Clinical trial NCT05802693 · UNKNOWN

Trial details

NCT number
NCT05802693
Sponsor
Beijing Tsinghua Chang Gung Hospital
Status
UNKNOWN
Phase
Early Phase 1
Study type
INTERVENTIONAL
Recurrent Glioblastoma
Start date
2023-11-15
Primary completion
2025-11-14
Enrollment
22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.